Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398268 | 1.00 | HTR2C (0.44) | HTR2CDDB1CRBNHTR2AHTR2B | |
| SCHEMBL20561574 | 0.89 | HTR2C (0.42) | HTR2CDDB1CRBNHTR2AHTR2B | |
| SCHEMBL20561573 | 0.89 | HTR2C (0.42) | HTR2CDDB1CRBNHTR2AHTR2B | |
| SCHEMBL10399467 | 0.76 | CYP3A4 (0.35) | HTR2A | |
| SCHEMBL8625311 | 0.76 | MEN1 (0.42) | HTR2CHTR2AHTR2BTSHR | |
| SCHEMBL13953886 | 0.76 | KDM1A (0.42) | HTR2CHTR2BTNKS2KDM1ASLC6A2 | |
| SCHEMBL16755274 | 0.76 | ALDH1A1 (0.42) | HTR2CHTR2AHTR2BKDM1ASLC6A2 | |
| SCHEMBL511920 | 0.76 | DPP4 (0.42) | HTR2CHTR2AHTR2BPBRM1TNKS2 | |
| SCHEMBL17747344 | 0.76 | HTR2C (0.53) | HTR2CHTR2AHTR2B | |
| SCHEMBL16398448 | 0.76 | HTR2C (0.53) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004120-B1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | UNIV NANYANG TECH (SG) | 2018-08-29 | — | — | EP | disclosed |
| CN-105658656-A | 1, 1' -spiroindane-7, 7-bisphosphine oxides as highly active supporting ligands in palladium-catalyzed asymmetric Heck reactions | 南洋理工大学 | 2016-06-08 | — | — | CN | disclosed |
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-19 | — | — | US | disclosed |
| EP-3004120-A1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | Nanyang Technological University (SG) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196930-A1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | SBK1, SIK1, PDPK1 | HTR2C 1658/4885DDB1 818/4885CRBN 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.